Commentary on Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer
As the cost of health care rises globally, there is a pressing need to recognize that ever-escalating treatment costs must be matched by improved outcomes; resources spent on care that delivers no benefit may deprive others of beneficial care. As such, we welcome the manuscript by Parikh et al,1 who seek to estimate the cost-effectiveness of stereotactic radiation therapy for oligometastatic prostate cancer.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Katie L. Spencer, Alison C. Tree Tags: Clinical Investigation Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Health Management | Hormones | Physics | Prostate Cancer | Radiation Therapy | Radiology